Kvien TK (2004) Epidemiology and burden of illness of rheumatoid arthritis. PharmacoEconomics 22:1–12. https://doi.org/10.2165/00019053-200422001-00002

Article  PubMed  Google Scholar 

D’Angelo S, Tirri E, Giardino AM, Mattucci-Cerinic M, Dagna L, Santo L et al (2022) Effectiveness of golimumab as second Anti-TNFα drug in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis in Italy: GO-BEYOND, a prospective Real-World observational study. J Clin Med 11:4178. https://doi.org/10.3390/jcm11144178

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hernández-Alava M, Pudney S (2017) Econometric modelling of multiple self-reports of health States: the switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis. J Health Econ 55:139–152. https://doi.org/10.1016/j.jhealeco.2017.06.013

Article  PubMed  PubMed Central  Google Scholar 

Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S et al (2014) The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis. Semin Arthritis Rheum 44:123–130. https://doi.org/10.1016/j.semarthrit.2014.05.001

Article  PubMed  Google Scholar 

Torlinska B, Raza K, Filer A, Jutley G, Sahbudin I, Singh R et al (2024) Predictors of quality of life, functional status, depression and fatigue in early arthritis: comparison between clinically suspect arthralgia, unclassified arthritis and rheumatoid arthritis. BMC Musculoskelet Disord 25:307. https://doi.org/10.1186/s12891-024-07446-6

Article  PubMed  PubMed Central  Google Scholar 

Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS (2004) Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43:906–914. https://doi.org/10.1093/rheumatology/keh199

Article  CAS  PubMed  Google Scholar 

Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:S685–S699. https://doi.org/10.1136/annrheumdis-2019-216655

Article  CAS  Google Scholar 

Fraenkel L, Bathon JM, England BR, St.Clair EW, Arayssi T, Carandang K et al (2021) 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 73:1108–1123. https://doi.org/10.1002/art.41752

Article  PubMed  Google Scholar 

Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M et al (2006) EULAR recommendations for the management of early arthritis: report of a task force of the European standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 66:34–45. https://doi.org/10.1136/ard.2005.044354

Article  PubMed  PubMed Central  Google Scholar 

van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJJ, Brouwer E, Codreanu C, Combe B et al (2017) EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis 76:491–496. https://doi.org/10.1136/annrheumdis-2016-209846

Article  PubMed  Google Scholar 

Burgers LE, Raza K, van der Helm-Van Mil AH (2019) Window of opportunity in rheumatoid arthritis-Definitions and supporting evidence: from old to new perspectives. RMD Open 5:V. https://doi.org/10.1136/rmdopen-2018-000870

Article  Google Scholar 

Frazzei G, Musters A, de Vries N, Tas SW, van Vollenhoven RF Prevention of rheumatoid arthritis: A systematic literature review of preventive strategies in at-risk individuals. Autoimmun Rev 2022:103217. https://doi.org/10.1016/j.autrev.2022.103217

Krijbolder DI, Verstappen M, van Dijk BT, Dakkak YJ, Burgers LE, Boer AC et al (2022) Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet 400:283–294. https://doi.org/10.1016/S0140-6736(22)01193-X

Article  PubMed  Google Scholar 

Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S et al (2024) Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet 403:838–849. https://doi.org/10.1016/S0140-6736(23)02649-1

Article  CAS  PubMed  Google Scholar 

Rech J, Tascilar K, Hagen M, Kleyer A, Manger B, Schoenau V et al (2024) Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet 403:850–859. https://doi.org/10.1016/S0140-6736(23)02650-8

Article  CAS  PubMed  Google Scholar 

Khidir SJH, de Jong PHP, van der Willemze A, van Mulligen E (2024) Clinically suspect arthralgia and rheumatoid arthritis: patients’ perceptions of illness. Joint Bone Spine 91:105751. https://doi.org/10.1016/j.jbspin.2024.105751

Article  PubMed  Google Scholar 

Courel-Ibáñez J, Vetrovsky T, Růžičková N, Marañón C, Durkalec-Michalski K, Tomcik M et al (2024) Integrative non-pharmacological care for individuals at risk of rheumatoid arthritis. Rheumatol Int 44:413–423. https://doi.org/10.1007/s00296-023-05507-y

Article  CAS  PubMed  Google Scholar 

Rech J, Ostergaard M, Tascilar K, Hagen M, Valor Mendez L, Kleyer A, Hueber AJ (2021) Abatacept reverses subclinical arthritis in patients with high-risk to develop rheumatoid arthritis-results from the randomized, placebo-controlled ARIAA study in RA-at risk patients. Arthritis Rheumatol;73

van Mulligen E, Bour SS, Goossens LMA, de Jong PHP, van der Rutten-van Mölken M Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial. Ann Rheum Dis 2024:ard-2024-226286. https://doi.org/10.1136/ard-2024-226286

Bowrin K, Briere J-B, Levy P, Millier A, Clay E, Toumi M (2019) Cost-effectiveness analyses using real-world data: an overview of the literature. J Med Econ 22:545–553. https://doi.org/10.1080/13696998.2019.1588737

Article  PubMed  Google Scholar 

van Steenbergen HW, van Nies JAB, Huizinga TWJ, Bloem JL, van der Reijnierse M (2015) Helm-van Mil AHM. Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI. Ann Rheum Dis 74:1225–1232. https://doi.org/10.1136/annrheumdis-2014-205522

Article  CAS  PubMed  Google Scholar 

van der Helm A, Boxma-de Klerk BM, van Steenbergen H, van Mulligen E, Verstappen M, van Dijk BT et al Early recognition and prevention of RA n.d. https://www.lumc.nl/en/about-lumc/afdelingen/reumatologie/rheumatoid-arthritis-ra/early-recognition-and-prevention-of-ra/ (accessed September 25, 2023).

Early recognition and prevention of RA n.d (2024) https://www.lumc.nl/afdelingen/reumatologie/rheumatoid-arthritis-ra/early-recognition-and-prevention-of-ra/

de Rooy DPC, van der Linden MPM, Knevel R, van der Huizinga TWJ (2011) Helm-van Mil AHM. Predicting arthritis outcomes–what can be learned from the Leiden. Early Arthritis Clinic? Rheumatol 50:93–100. https://doi.org/10.1093/rheumatology/keq230

Article  Google Scholar 

Federatie Medisch Specialisten (2023) https://richtlijnendatabase.nl/richtlijn/reumato_de_artritis_ra/startpagina_-_reumatoide_artritis.html (accessed March 25, 2025)

Devlin N, Parkin D, Janssen B (2020) Methods for analysing and reporting EQ-5D data. Springer International Publishing, Cham. https://doi.org/10.1007/978-3-030-47622-9

Book  Google Scholar 

Versteegh M, Vermeulen MM, Evers KMAA, de Wit S, Prenger GA, Stolk RA (2016) Dutch tariff for the Five-Level version of EQ-5D. Value Health 19:343–352. https://doi.org/10.1016/j.jval.2016.01.003

Article  Google Scholar 

Cheng LJ, Chen LA, Cheng JY, Herdman M, Luo N (2024) Systematic review reveals that EQ-5D minimally important differences vary with treatment type and May decrease with increasing baseline score. J Clin Epidemiol 174:111487. https://doi.org/10.1016/j.jclinepi.2024.111487

Article  PubMed  Google Scholar 

Gabrio A, Plumpton C, Banerjee S, Leurent B (2022) Linear mixed models to handle missing at random data in trial-based economic evaluations. Health Econ 31:1276–1287. https://doi.org/10.1002/hec.4510

Article  PubMed  PubMed Central  Google Scholar 

van Delft MAM, Huizinga TWJ (2020) An overview of autoantibodies in rheumatoid arthritis. J Autoimmun 110:102392. https://doi.org/10.1016/j.jaut.2019.102392

Article  CAS  PubMed  Google Scholar 

ten Brinck RM, van Steenbergen HW, Mangnus L, Burgers LE, Reijnierse M, Huizinga TW et al (2017) Functional limitations in the phase of clinically suspect arthralgia are as serious as in early clinical arthritis; a longitudinal study. RMD Open 3:e000419. https://doi.org/10.1136/rmdopen-2016-000419

Article  PubMed  PubMed Central  Google Scholar 

Krijbolder DI, Khidir SJH, van der Helm AH (2023) To treat or not to treat? Current attitudes on treatment aimed at modifying the disease burden in clinically suspect arthralgia: a survey among participants of the TREAT EARLIER trial and healthcare professionals. RMD Open 9:e003031. https://doi.org/10.1136/rmdopen-2023-003031

Article  PubMed  PubMed Central  Google Scholar 

Khidir SJH, van der Wouters F, van Mulligen E (2022) The course of fatigue during the development of rheumatoid arthritis and its relation with inflammation: a longitudinal study. Joint Bone Spine 89:105432. https://doi.org/10.1016/j.jbspin.2022.105432

Article  PubMed